Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Ovarian Cancer (BRCA1, BRCA2, Homologous Recombination Deficiency, Tumor Mutational Burden, Microsatellite Instability/Mismatch Repair)

Biomarker-targeted therapy has shown a clear survival benefit in patients with ovarian cancer. More recently, testing for microsatellite instability/mismatch repair (MSI/MMR) and tumor mutational burden (TMB) status to select patients for immunotherapy has been proposed. Typically, the evaluation of biomarker status requires tissue biopsy. Circulating tumor DNA testing (also known as a liquid biopsy) is proposed as a non-invasive alternative.